Trajan Group Posts Record Q2 Revenue, Maintains $16M+ nEBITDA Guidance
Trajan H1 FY26 Results: Record Q2 revenue and maintained guidance signal recovery
Trajan Group Holdings Limited has delivered record Q2 revenue in its Trajan Group H1 FY26 Results, signalling recovery momentum after a challenging start to the half-year period. The analytical and life sciences company reported H1 FY26 Group Revenue of $84.1M, up 3.8% on the prior corresponding period (PCP) of $81.0M, while Group nEBITDA came in at $5.0M, down 36.2% from $7.9M in H1 FY25. Despite the earnings compression, management maintained full-year guidance of Net Revenue $170M+ and Group nEBITDA $16M+, reflecting confidence in a second-half recovery driven by improving market conditions and internal margin initiatives.
The company’s H1 performance represents a tale of two quarters. Q1 faced headwinds including purchasing caution in Capital Equipment, slowdowns in pharmaceutical and food sectors, and a US Government funding freeze. However, Q2 delivered record group revenue, with the Capital Equipment order book growing by $2.8M during H1 to finish at $10.8M heading into the second half. Cash balance improved to $12.7M, up 6.7% from $11.9M at 30 June 2025, providing financial flexibility as recovery takes hold.
When big ASX news breaks, our subscribers know first
What drives Trajan’s three operating segments?
Trajan operates through three distinct business segments, each contributing to revenue diversification and resilience against sector-specific downturns. Components & Consumables delivers recurrent revenue through analytical products sold to global OEM partners and laboratory end-users. Capital Equipment provides instrumentation, software and automation systems for clinical, pharmaceutical, food and environmental sample analysis. Disruptive Technologies encompasses innovative microsampling devices and miniaturised liquid chromatography platforms targeting decentralised analytical monitoring.
The segment-level performance in H1 FY26 demonstrates how diversification protects against market volatility, with Components & Consumables and Disruptive Technologies posting revenue growth while Capital Equipment navigated near-term softness.
| Segment | H1 FY26 Revenue | Change vs PCP | Segment nEBITDA | Gross Margin |
|---|---|---|---|---|
| Components & Consumables | $51.9M | +6.1% | $15.2M | 37.5% |
| Capital Equipment | $29.1M | -2.7% | $4.8M | 35.3% |
| Disruptive Technologies | $3.1M | +40.2% | ($0.3M) | 53.6% |
This diversified portfolio positions Trajan to capture growth across multiple end markets whilst providing downside protection. The standout 40.2% growth in Disruptive Technologies signals emerging commercial traction in next-generation analytical devices, whilst Components & Consumables continues to deliver steady, recurring revenue even in challenging market conditions.
Components & Consumables posts steady growth despite margin pressure
The Components & Consumables segment delivered revenue of $51.9M, up 6.1% from $48.9M in the prior corresponding period. This growth came despite difficult market conditions, demonstrating the segment’s resilience and the sticky nature of Trajan’s customer relationships with large global OEM partners. The company’s “in region for region” manufacturing capability has proven particularly valuable, with management noting that a major OEM customer is “delighted” with Trajan’s ability to pivot production geographically in response to tariff and supply chain disruptions.
However, gross margin compressed to 37.5%, down 3.7 percentage points from 41.2% in H1 FY25, reflecting production site inefficiencies and inter-site costs incurred whilst establishing regional manufacturing capabilities. Segment nEBITDA of $15.2M declined 6.3% from $16.3M as margin pressure offset revenue growth. Management expects these inefficiencies to improve in H2 as regional operations mature and growth in emerging consumable areas accelerates.
Capital Equipment order book builds momentum for H2
The Capital Equipment segment reported revenue of $29.1M, down 2.7% from $29.9M in the prior period, as purchasing caution in pharmaceutical and food sectors weighed on near-term sales. Segment nEBITDA of $4.8M declined 14.3% from $5.6M, with gross margin slipping 0.9 percentage points to 35.3%. Despite the revenue softness, the segment demonstrated clear forward momentum through a growing order pipeline.
The critical forward indicator for this segment is the order book balance, which grew by $2.8M during H1 to finish at $10.8M heading into the second half. This provides visibility for H2 revenue conversion as delayed customer projects move forward. Pharmaceutical market activity, particularly in the European Union, has picked up markedly, whilst new clinical systems are expected to contribute to H2 performance. Management also highlighted potential future growth opportunities from regulatory changes, such as more stringent olive oil monitoring requirements in the EU, which could drive demand for Trajan’s analytical instrumentation.
Disruptive Technologies hits profitability milestone in microsampling
Disruptive Technologies delivered the standout performance of H1, with revenue surging 40.2% to $3.1M from $2.2M in the prior period. The segment achieved a critical commercial milestone as the Microsampling portfolio now operates at a profit, validating years of investment in next-generation analytical devices. Segment nEBITDA improved 69.4% to a loss of just ($0.3M) compared to a ($1.0M) loss in H1 FY25, demonstrating rapid progress toward breakeven.
The revenue growth reflects a fundamental shift in the commercial model, with microsampling device sales moving from isolated proof-of-concept studies to repeat business from established customers. This transition signals that early adopters are validating the technology and expanding usage. The Versiti platform, Trajan’s miniaturised liquid chromatography system, is now installed at multiple sites across the United States and Australia, further advancing commercialisation. With a gross margin of 53.6%, the segment demonstrates strong unit economics once scale is achieved, positioning it as a future growth driver for the group.
The path to $16M nEBITDA: management’s H2 bridge
Management has provided a detailed pathway to achieving full-year nEBITDA guidance of $16M+, requiring approximately $11M in H2 performance compared to $5.0M delivered in H1. The bridge relies on four key levers, with the majority of initiatives already implemented and expected to flow through to earnings in the second half. This transparency provides investors with visibility on how Trajan plans to deliver on its commitments despite the challenging H1 result.
- H2 baseline nEBITDA at Q2 run rate: $8.6M
- Project Neptune cost reductions (headcount and facilities): +$0.8M
- Pricing actions (effective 1 January 2026): +$1.3M
- Supply chain and growth initiatives: +$0.3M
The H2 baseline of $8.6M reflects the Q2 run rate, indicating that even without additional actions, the business has already returned to a stronger earnings trajectory. Project Neptune cost reductions were implemented in November and December 2025, targeting headcount and facilities rationalisation. Pricing actions took effect from 1 January 2026, providing a full quarter of benefit in Q3 and Q4. Management flagged one material risk to the bridge: potential AUD revaluation of offshore assets, which could impact reported earnings if the Australian dollar strengthens significantly against major currencies.
Industry tailwinds support Trajan’s recovery thesis
Trajan’s recovery outlook is underpinned by improving sector-wide conditions and external validation from industry peers. Major analytical instrument companies including Agilent and Thermo Fisher Scientific are guiding calendar year 2026 growth rates of 4-6%, signalling a broad-based return to growth across life sciences and analytical markets. This provides confidence that Trajan’s H2 expectations are not based on company-specific optimism, but rather align with sector-wide recovery trends.
A critical overhang was removed on 8 February 2026, when US President Trump authorised funding to the National Institutes of Health (NIH), Centers for Disease Control (CDC), and other US Government science agencies. The earlier funding freeze had created purchasing caution among Capital Equipment customers, delaying project approvals and equipment orders. With funding now released, deferred projects are expected to move forward, supporting order conversion in H2.
Key tailwinds supporting H2 performance include:
- Pharmaceutical sector recovering from prior-period caution
- Capital Equipment food sector orders beginning to flow
- US Government science funding approved and releasing
- Industry peers reporting return to growth across analytical markets
These external factors complement Trajan’s internal margin initiatives, creating a favourable environment for the company to deliver on its full-year guidance whilst rebuilding momentum heading into FY27.
The next major ASX story will hit our subscribers first
What’s next for Trajan investors?
Trajan has delivered a resilient H1 result despite significant macro headwinds, maintaining revenue growth whilst absorbing margin pressure from “in region for region” establishment costs. The maintained full-year guidance of Net Revenue $170M+ and Group nEBITDA $16M+ signals management confidence in H2 recovery, supported by record Q2 revenue, a growing Capital Equipment order book, and implemented pricing actions. The diversified business model across three operating segments has proven its value, with Components & Consumables and Disruptive Technologies offsetting Capital Equipment softness.
Key catalysts for H2 include conversion of the $10.8M Capital Equipment order book, margin improvement from Project Neptune efficiencies, full benefit from pricing actions implemented 1 January 2026, and continued momentum in Disruptive Technologies as microsampling transitions to repeat commercial sales. Investors should monitor the FY26 full-year result for guidance delivery, which would validate the turnaround narrative and position the company for renewed growth in FY27 as sector tailwinds strengthen.
Get Life Sciences News Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. The Big News Blast alert service delivers market-moving announcements from Healthcare, Biotech, and MedTech sectors straight to your inbox. Click the “Free Alerts” button to stay ahead on the next analytical sciences breakthrough.